Vincent Lepreux
Investment Principal @ Debiopharm Innovation Fund
Vincent Lepreux is an Investment Director at Debiopharm Innovation Fund
- Total investments:
- 5
- Last investment:
- Lead investor:
- 80%
Last updated:
For AI agents: llms.txt
Industries Vincent Lepreux invests in
Stages Vincent Lepreux invests in
Countries Vincent Lepreux invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Software 2 (40%)
- Health Care 2 (40%)
- Pharmaceutical 2 (40%)
- B2B 1 (20%)
- PaaS 1 (20%)
Stage
- Seed 2 (40%)
- Series A 1 (20%)
- Funding Round 1 (20%)
Country
- United States 2 (40%)
- Israel 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| A cloud platform empowering global expanded and managed access programs. | Seed / Mar 05, 2025 | ||
| Clinical Maestro™ by Strategikon Pharma is the only commercially available software platform for the end- to- end management of “clinical business operations”, which is the pharmaceutical industry vertical for planning, outsourcing and budgeting clinical trials. Biopharmaceutical companies outsource 90% of their clinical development pipelinespending billions of dollars engaging in highly complex outsourced relationships with thousands of global service providers, each using their own processes, systems and reporting structures. These sophisticated relationships require complex outsourcing strategies, demanding clinical financial planning, extensive sourcing due diligence and rigorous performance management. Currently the industry manages these activities in Excel, using labor intensive, inefficient processes, costing billions of dollars in infrastructure costs, regulatory non-compliance fines and delays to market. Clinical Maestro takes a radically different approach to the management of clinical portfolio through a transformative redesign of Excel-driven processes into end-to-end integrated workflows, breaking the communication and data integration siloes between pharma companies and their outsourcing partners. Clinical Maestro™ cases studies with leading pharmaceutical companies and CROs demonstrate savings of >80% vs. manual processes, >95% prediction accuracy for clinical study budgets and high user satisfaction and engagement. | $7M / Series A / Feb 06, 2024 | ||
| A cloud platform empowering global expanded and managed access programs. | Seed / Jan 09, 2024 | ||
| YonaLink is a global network of over 30,000 medical centers that provides EHR-to-EDC streaming and AI-driven CRF data mapping. YonaLink collects clinical trial data in real-time, improves trial efficiency and data quality, reduces medical center staff burnout, and provides wider access to novel patient care opportunities. | $6M / Seed / Nov 08, 2022 | ||
| See all 5 investments → | |||
Co-Investors
Debiopharm Innovation Fund invests in digital health companies that have an impact on cancer, infectious diseases, and drug development. We are looking for ambitious entrepreneurs raising series A or B with clinically proven, transformative technologies that use AI and data to help patients. We do not invest in consumer wellness or workflowsolutions. Our initial investment is typically $2-5M. Along with capital we bring deep pharma knowledge & networks and long-term commitment to help build value in your company. We are an evergreen investment fund of the pharmaceutical company Debiopharm based in Lausanne, Switzerland.
Debiopharm Innovation Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Cedric Odje
Senior Investment Associate
|
|||
|
Nicole Wilson
Senior Administrative Assistant
|
|||
Tanja Dowe
Chief Executive Officer
|
|||
Thomas Gibbs
Director
|
|||
|
Vincent Lepreux
Investment Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Vincent Lepreux invest in?
Vincent Lepreux invests primarily in Software, Health Care and Pharmaceutical startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Vincent Lepreux?
Public channels for Vincent Lepreux include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Vincent Lepreux last invest?
The most recent investment recorded for Vincent Lepreux closed in Mar 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
